Idelalisib Phase III Clinical Trial for previo... - CLL Support

CLL Support

22,504 members38,653 posts

Idelalisib Phase III Clinical Trial for previously treated CLL

Cllcanada profile image
CllcanadaTop Poster CURE Hero
1 Reply

I'm posting information about this trial because it has many U.K. locations and a number in France and Italy.

quote

This is a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia.

Eligible patients will be randomized with a 1:1 ratio into 1 of the 2 treatment arms to receive either Idelalisib or placebo. All subjects will be administered rituximab. Subjects who are tolerating primary study therapy but experience definitive CLL progression are eligible to receive active Idelalisib therapy in the extension study, GS-US-312-0117.

end quote

LINK see locations on this page...

clinicaltrials.gov/ct2/show...

Written by
Cllcanada profile image
Cllcanada
Top Poster CURE Hero
To view profiles and participate in discussions please or .
Read more about...
1 Reply
HAIRBEAR_UK profile image
HAIRBEAR_UKFounder Admin

Thanks Chris -

Other UK Clinical trial information resources

The UK Clinical Trials Gateway – CLL trials information: ukctg.nihr.ac.uk/search?que...

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

ukctg.nihr.ac.uk/trialdetai...

Current NCRN UK CLL clinical trials map.

ncrndev.org.uk/downloads/Tr...

You may also like...

UK Clinical Trial with B + R -- Idelalisib (GS-1101) OR CAL 101 Study (III)

September - Clinical trial update - B + R and Idelalisib - CAL 101

that I am actually receiving the trial drug Idelalisib (CAL 101.) and not the placebo, due to the...

AVO clinical trial for CLL

FDA Grants Special Protocol Assessment to Phase III Ublituximab/Ibrutinib Study

bIbrutinib-Study Watch out for more combination therapies with ibrutinib and Idelalisib. Neil...

A071402 Phase 3 clinical trial - Obinituzumab+Ibrutinib+Venetoclax